甘精胰岛素与双相门冬胰岛素用于初诊2型糖尿病患者胰岛素泵治疗后的疗效比较

目的比较甘精胰岛素（来得时）和双相门冬胰岛素（诺和锐30）皮下注射应用于初诊T2DM短期持续皮下胰岛素输注（CSII）治疗后的疗效。方法60例初诊T2DM患者应用CSII治疗后，随机分为以诺和锐30治疗的BIAsp30组和以来得时治疗的Lantus组。比较两组7个时点血糖、HbA1c、低血糖事件及其他不良事件的差异。结果与BIAsp30组相比，Lantus组20周后三餐后血糖水平明显降低，低血糖事件发生次数低（P均〈0．05）；两组FPG、HbA1c及不良事件差异无统计学意义（P均〉0．05）。结论初诊T2DM患者CSII治疗所用Ins剂量相同且血糖达标后，采用来得时睡前1次注射，比早、晚餐前诺和锐30皮下注射治疗者全天血糖控制满意，且低血糖事件发生率低。

The efficacy comparison between glargine and biphasic insulin aspart 30(BIAsp 30) after CSII in newly diagnosed type 2 diabetes mellitus

Objective To compare the efficacy and safety of glargine（Lantus） versus biphasic insulin aspart 30 （30% free and 70% protamine-bound, BIAsp 30） after continuous subcutaneous insulin infusion treatment （CSII） in newly diagnosed type 2 diabetes mellitns. Methods A 20 week open and random study was performed. All 60 patients with newly diagnosed T2DM were randomly divided into two groups. Group B patients was treated by glargine and group A received treatment with BIAsp 30 administered immediately before dinner and breakfast. Blood glucose at 7 time points, glycosylated hemoglobin Ale（HbA1c） and hypoglycemia were observed. Results The postprandial glucose（PPG） was significantly lower in group B than in group A （P〈0. 05）, and the frequency of hypoglycaemic episodes was lower in group B than in group A （P〈0.05）. The fasting blood glucose（FBG） was not different between two groups （P〈0.05）. And there was no difference between two groups in HbA1c and other adverse events. Conclusions Glargine is surperior to BIAsp30, not only in controlling the PPG but also in reducing the incidence of hypoglycemia.